Clinical Trial Update: Nilotinib for First-line Newly Diagnosed CML-CP Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update investigating nilotinib as first-line therapy for newly diagnosed chronic myeloid leukemia in the chronic phase.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Shenzhen Second People's Hospital | Conditions: Chronic Myeloid Leukemia, Chronic Phase, Nilotinib | Phase 3 | Status: UNKNOWN